XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Service Receivable
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance, beginning (in shares) at Dec. 31, 2020   716 36,781        
Balance, beginning at Dec. 31, 2020 $ 128,158 $ 1 $ 4 $ 361,819 $ (2,171) $ 0 $ (231,495)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 268     268      
Issuance of common stock upon exercise of warrants (in shares)     771        
Issuance of common stock upon exercise of warrants 1,263     1,263      
Other comprehensive gain (loss) (67)         (67)  
Preferred stock dividend (6)           (6)
Release of clinical trial funding commitment 380       380    
Net loss (5,179)           (5,179)
Balance, ending (in shares) at Mar. 31, 2021   716 37,552        
Balance, ending at Mar. 31, 2021 124,817 $ 1 $ 4 363,350 (1,791) (67) (236,680)
Balance, beginning (in shares) at Dec. 31, 2020   716 36,781        
Balance, beginning at Dec. 31, 2020 128,158 $ 1 $ 4 361,819 (2,171) 0 (231,495)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (11,936)            
Balance, ending (in shares) at Jun. 30, 2021   716 39,552        
Balance, ending at Jun. 30, 2021 138,918 $ 1 $ 4 383,611 (1,245) (10) (243,443)
Balance, beginning (in shares) at Mar. 31, 2021   716 37,552        
Balance, beginning at Mar. 31, 2021 124,817 $ 1 $ 4 363,350 (1,791) (67) (236,680)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,036     1,036      
Sale of common stock, net of expenses (in shares) [1]     2,000        
Sale of common stock, net of expenses [1] 19,225     19,225      
Other comprehensive gain (loss) 57         57  
Preferred stock dividend (6)           (6)
Release of clinical trial funding commitment 546       546    
Net loss (6,757)           (6,757)
Balance, ending (in shares) at Jun. 30, 2021   716 39,552        
Balance, ending at Jun. 30, 2021 138,918 $ 1 $ 4 383,611 (1,245) (10) (243,443)
Balance, beginning (in shares) at Dec. 31, 2021   716 41,964        
Balance, beginning at Dec. 31, 2021 140,417 $ 1 $ 4 400,503 (139) (142) (259,810)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,152     1,152      
Other comprehensive gain (loss) (606)         (606)  
Issuance of common stock upon conversion of Series E Convertible Preferred Stock (in shares)   (328) 1,342        
Issuance of common stock upon conversion of Series E Convertible Preferred Stock (1) $ (1)          
Preferred stock dividend (6)           (6)
Release of clinical trial funding commitment 139       139    
Net loss (10,993)           (10,993)
Balance, ending (in shares) at Mar. 31, 2022   388 43,306        
Balance, ending at Mar. 31, 2022 130,102 $ 0 $ 4 401,655 0 (748) (270,809)
Balance, beginning (in shares) at Dec. 31, 2021   716 41,964        
Balance, beginning at Dec. 31, 2021 140,417 $ 1 $ 4 400,503 (139) (142) (259,810)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (21,436)            
Balance, ending (in shares) at Jun. 30, 2022   388 43,306        
Balance, ending at Jun. 30, 2022 120,474 $ 0 $ 4 402,710 0 (982) (281,258)
Balance, beginning (in shares) at Mar. 31, 2022   388 43,306        
Balance, beginning at Mar. 31, 2022 130,102 $ 0 $ 4 401,655 0 (748) (270,809)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 1,055     1,055      
Other comprehensive gain (loss) (234)         (234)  
Preferred stock dividend (6)           (6)
Net loss (10,443)           (10,443)
Balance, ending (in shares) at Jun. 30, 2022   388 43,306        
Balance, ending at Jun. 30, 2022 $ 120,474 $ 0 $ 4 $ 402,710 $ 0 $ (982) $ (281,258)
[1] Net of expenses of $0.8 million.